Breakthrough discovery in cancer therapy
Sartar Therapeutics was established to advance a breakthrough discovery in cancer therapy. Using gene expression profiling, we found exceptionally high phosphodiesterase 3A (PDE3A) gene expression in gastrointestinal stromal tumor (GIST), other soft tissue sarcoma subtypes and subsets of other cancers. Our discovery of a novel cancer target, PDE3A, represents a significant leap in cancer therapy.
Innovative precision treatment
We are developing SAR003, a first-in-class breakthrough targeted therapy for cancers expressing the PDE3A gene. Our first indication is gastrointestinal stromal tumour (GIST), a cancer where all tumors express the PDE3A gene.
We have strong IP, patent protection and Orphan Drug Designations (ODD) from EMA and FDA for the treatment of GIST using SAR003.
SAR003 functions as a molecular glue to induce cancer cell death in rapidly dividing cancer cells. Our preclinical proof-of-concept data from sophisticated in vivo models shows outstanding efficacy.
Read more
Sartar Team
Sartar is a company dedicated to the development of targeted therapies for hard-to-treat cancers. Our experienced team is supported by key leading clinical opinion leaders in Europe and US, and a world class vendor network.
Read moreNews
Today is the international GIST Awareness Day!
Gastrointestinal stromal tumour (GIST) is a rare cancer that presents in various forms and can affect individuals of all ages. The prognosis for metastatic GIST is poor. All current targeted therapies rely on tyrosine kinase inhibitors, which control disease progression for a limited time before patients exhaust available treatment options. Moreover, pediatric, adolescent, wild-type, and […]
Read article
July is the sarcoma awareness month
Sarcomas are rare, difficult-to-diagnose, and hard-to-treat cancers that can affect people of any age, accounting for up to 20% of all adolescent cancers. These cancers originate from different tissue types, resulting in many subtypes, such as gastrointestinal stromal tumors (GIST), liposarcomas, and leiomyosarcomas. They often grow undetected until they reach an advanced stage. This highlights […]
Read article
Meet our CEO in LSX World Congress 2024!
Meet our CEO Mikael Maksimow in the LSX World Congress in London on 29-30 April 2024!
Read article